TANK-binding kinase 1 (TBK1) and its homolog IκB kinase (IKK) epsilon (IKKε, also known as IKKi) are serine/ threonine kinases that are well known for their functions to mediate type I interferon (IFN-I) induction in antiviral innate immune responses. 1 Various microbial components, or pathogen associated molecular patterns (PAMPs), activate TBK1 and IKKε via stimulating pattern-recognition receptors (PRRs) in innate immune cells. Upon activation, TBK1 or IKKε (hereafter called TBK1/ IKKε) phosphorylates the transcription factors IRF3 and IRF7 to trigger their dimerization and nuclear translocation, leading to induction of IFN-I gene expression. 1, 2 In this innate immune signaling pathway, TBK1 and IKKε display functional redundancies, although TBK1 seems to be more crucial than IKKε. 3, 4 It is increasingly clear that the function of TBK1 and IKKε is beyond the regulation of antiviral innate immunity. These kinases have non-redundant functions in various other physiological and pathological processes, such as adaptive immunity, oncogenesis, and autophagy ( Figure 1 ). [5] [6] [7] [8] [9] In particular, recent studies have uncovered a pivotal role for TBK1 in regulating T cell homeostasis and autoimmunity and implicated TBK1 as a modulator of antitumor immune responses. 10, 11 The study of in vivo functions of TBK1 has been hampered by the lack of a viable animal model, since the conventional TBK1 knockout (KO) mice are embryonic lethal. 12 Nevertheless, a number of studies have shown that TBK1 responds to signals from diverse receptors, such as TNF receptor (TNFR) superfamily members, T cell receptor (TCR), B cell receptor (BCR), as well as various PRRs, many of which do not induce IFN-I expression (Figure 1) . 6, 7, 13, 14 The recent development of TBK1-conditional KO mice has led to the characterization of novel functions of TBK1 in the regulation of adaptive immune responses and homeostasis ( Figure 1 ). TBK1 functions in B cells to negatively regulate noncanonical NF-κB activation by TNFR superfamily members, including CD40 and BAFFR, which involves phosphorylation of the noncanonical NF-κB inducing kinase (NIK) for ubiquitin-dependent degradation. 6 This function is crucial for controlling IgA class switching, and mice carrying B cell-specific deletion of TBK1 develop a nephropathy-like disease, characterized by heightened serum IgA concentration and antibody deposition onto kidney glomeruli. 6 In T cells, TBK1 controls the steady-state level of AKT, which in turn is important for maintaining T cell homeostasis and preventing abnormal T cell activation. 7 Unlike the TAK1-IKK signaling axis, 15 TBK1 does not seem to regulate the survival or function of regulatory T cells but rather exerts a cellintrinsic role to regulate T cell homeostasis. 7 TBK1 also has a role in regulating T cell migration to the central nervous system in an autoimmune neuroinflammation model. 7 In contrast to TBK1, IKKε is dispensable for maintaining T cell homeostasis; 7 however, IKKε plays a role in negatively regulating T cell responses through inhibiting activation of the transcription factor NFATc1. 8 Recent studies from us and others suggest a function of TBK1 in regulating autoimmunity and antitumor immunity. 10, 11 Our work demonstrates that TBK1 functions in dendritic cells (DCs) to regulate immune tolerance and prevent the development of autoimmunity. 10 DCs are primary antigen-presenting cells (APCs) required for stimulating T cell responses to foreign antigens during an infection. Upon recognition of PAMPs via various PRRs, DCs are stimulated to undergo maturation and become competent APCs for T cell activation. 16 However, under homeostatic conditions, DCs are present in immature or partially matured states and induce T cell tolerance to self-antigens, which is critical for maintaining immune homeostasis and preventing autoimmunity. [16] [17] [18] In DCs isolated from peripheral lymphoid organs of healthy mice, TBK1 displays a basal level of activation, which is further elevated when the mice become older, suggesting that TBK1 is activated by undefined homeostatic stimuli, possibly cytokines or self-DNAs (Figure 2 ). 10 Although TBK1 is dispensable for DC development and homeostasis, the deletion of TBK1 in DCs perturbs T cell homeostasis, causing an increase in the frequency of memory-like CD4 + and CD8 + T cells, a phenotype that is particularly profound in older mice. The TBK1 DC-conditional knockout (TBK1-DKO) mice spontaneously develop autoimmune symptoms, including splenomegaly, lymphadenopathy, and tissue infiltration with lymphocytes. 10 The TBK1-DKO mice are also more sensitive to the induction of experimental autoimmune encephalomyelitis (EAE), 10 an animal model of multiple sclerosis known to be dependent on Th1 and Th17 subsets of inflammatory T cells. 19 These findings suggest that TBK1 is important for DC function in maintaining immune homeostasis and tolerance at steady state as well as in regulating activation of autoimmune T cells in organ-specific autoimmunity (Figure 2) .
While immune tolerance prevents development of autoimmune diseases, it is also a major obstacle for immune responses against cancer, and breaking immune tolerance has been exploited as an approach to boost anti-tumor immune responses in cancer immunotherapy. 20, 21 In transplantable murine melanoma and thymoma models, DC-specific deletion of TBK1 causes significantly reduced tumor growth and increased survival rate of the tumorbearing mice, associated with enhanced T cell activation in draining lymph nodes and effector T cell infiltration into the tumor tissue. 10 When the DC-specific TBK1 deficiency is combined with treatment with a blocking antibody of the T cell checkpoint molecule PD-1, it results in a marked synergistic effect in the suppression of tumor growth. This finding is corroborated by a more recent study using an organotypic tumor spheroid technique. 11 In this ex vivo approach, pharmacological inhibition of TBK1 and IKKε also greatly potentiates the induction of anticancer immunity by PD-1 blockade using an anti-PD-L1 antibody. Moreover, treatment of mice bearing the CT26 colorectal tumor with anti-PD-L1 and TBK1 inhibitor leads to greater tumor control and longer survival than single treatment with either anti-PD-L1 or TBK1 inhibitor. 11 Together, these two separate studies demonstrate an important role for TBK1 in regulating antitumor immunity and further emphasize the function of TBK1 in regulating immune tolerance (Figure 2 ). These findings also suggest the intriguing possibility that targeting TBK1 may be an approach to improve the efficacy of cancer immunotherapy.
The molecular mechanism by which TBK1 functions in DCs to regulate autoimmunity and antitumor immunity is only partially understood. TBK1 is activated in DCs under homeostatic conditions and further stimulated in the draining lymph nodes of tumor-bearing mice. 10 A prominent function of TBK1 is to negatively regulate DC maturation, since the TBK1-deficient DCs have upregulated expression of costimulatory molecules, CD80 and CD86, and exhibit stronger function in mediating T cell activation in vitro than the TBK1-sufficient DCs. Mechanistically, TBK1 negatively regulates expression of a subset of IFN-responsive genes in DCs, as revealed by RNA-sequencing analyses of splenic DCs isolated from wildtype and TBK1-DKO mice. 10 TBK1 deficiency also sensitizes DCs for in vitro gene induction by IFNβ. Given the critical role of IFN-Is in the induction of DC maturation and cross-priming function, 22 it is likely that regulation of IFN-induced signaling is a major mechanism by which TBK1 regulates DC function in T cell homeostasis and activation. Furthermore, this novel function of TBK1 appears to involve phosphorylation at serine 727 of STAT3, 10 a negative regulator of type I IFN-induced STAT1 activation and gene induction (Figure 2) . 23, 24 Consistently, DC-conditional deletion of STAT3 causes upregulated expression of IFN-responsive genes in DCs and perturbed T cell homeostasis, as seen in TBK1-DKO mice. 10 The functional connection of TBK1 with type I IFN response is further suggested by the finding that deletion of the type I IFN receptor (IFNAR1) gene in TBK1-DKO mice prevents aberrant T cell activation and autoimmunity and eliminates the differences between wildtype and TBK1-deficient DCs in mounting antitumor immunity.
In summary, the recent work highlighted here provides compelling evidence that TBK1 is a pivotal kinase that regulates DC functions in the maintenance of T cell homeostasis and prevention of autoimmune responses. TBK1 also regulates immune responses against tumorigenesis and serves as a putative drug target for boosting T cell responses in cancer immunotherapy. These findings, along with the reports showing the T cell-intrinsic role of TBK1 and IKKε in regulating T cell activation and homeostasis, 7, 8 suggest that the function of TBK1, as well as of its related kinase IKKε, in immune regulation is beyond the induction of antiviral innate immunity. Further studies using in vivo models may identify additional roles of these kinases in the immune system.
